DEST.L

Destiny Pharma Plc
Destiny Pharma PLC - Result of GM and Cancellation of Trading on AIM
31st July 2024, 10:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 5920Y
Destiny Pharma PLC
31 July 2024
 

Destiny Pharma plc

("Destiny Pharma" or "the Company")

 

Result of General Meeting and Cancellation of Admission to Trading on AIM

 

 

Brighton, United Kingdom - 31 July 2024 - Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development and commercialisation of novel medicines to prevent and cure life threatening infections, announces that, at the general meeting of the Company held earlier today (the "General Meeting"), all resolutions put to the Company's shareholders ("Shareholders") were duly passed.

 

The table below sets out the details of the votes put to Shareholders:

 

Special Resolution Number

Special Resolution Name

Votes for

Votes Against

Votes Withheld*

Total Votes Cast (excl. withheld)

No. of shares

% of shares voted

No. of shares

% of shares voted

No. of shares

1

Cancellation Resolution

 

36,177,977

 

87.82%

 

5,016,137

 

12.18%

 

48,982

41,194,114

2

Re-registration Resolution

 

36,329,435

 

88.19%

 

4,864,679

 

11.81%

 

48,982

41,194,114

3

Adoption of New Articles of Association Resolution

 

36,183,961

 

87.84%

 

5,010,153

 

12.16%

 

48,982

41,194,114

*A vote withheld is not a vote in law and is not counted in the calculation of the proportion of votes 'For' or 'Against'

 

In accordance with the passing of Resolutions 2 and 3, the Company will re-register as a private limited company with the name Destiny Pharma Limited and adopt new articles of association, which is expected to take place on or around 30 August 2024.

 

The full text of the resolutions proposed and passed at the General Meeting can be found in the circular containing, inter alia, the Notice of General Meeting, which was published and posted to Shareholders on 15 July 2024 and is available on the Company's website www.destinypharma.com (the "Circular").

 

AIM Delisting

 

Following approval by Shareholders at the General Meeting, the admission of the ordinary shares of 1 pence each in the capital of the Company (the "Ordinary Shares") to trading on AIM will be cancelled (the "AIM Delisting"). The AIM Delisting is expected to take place at 7.00 a.m. on 13 August 2024 and, accordingly, the last day of dealings in Ordinary Shares on AIM is expected to be 12 August 2024.

 

Matched Bargain Facility

 

It remains the Company's intention to provide a matched bargain facility to assist Shareholders wishing to trade in Ordinary Shares following the AIM Delisting. Further details with respect to the matched bargain facility, to be provided by J P Jenkins, will be made available in due course on the Company's website www.destinypharma.com.

 

Capitalised terms used but not defined in this announcement shall have the same meaning given to such terms in the Circular. 

 

For further information, please contact:

 

Destiny Pharma plc

Chris Tovey, CEO

Shaun Claydon, CFO

+44 (0)1273 704 440

pressoffice@destinypharma.com

 

FTI Consulting

Ben Atwell / Simon Conway

+44 (0) 203 727 1000

destinypharma@fticonsulting.com

 

Shore Capital (Nominated Adviser and Broker)

Daniel Bush / James Thomas / Lucy Bowden

+44 (0) 207 408 4090

 

About Destiny Pharma

Destiny Pharma is an innovative, clinical-stage biotechnology company focused on the development and commercialisation of novel medicines that can prevent life-threatening infections. The Company's drug development pipeline includes two late-stage assets XF-73 Nasal gel, a proprietary drug targeting the prevention of post-surgical staphylococcal hospital infections including MRSA and NTCD-M3, a microbiome-based biotherapeutic for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US.

 

For further information on the company, please visit www.destinypharma.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ROMKFLBXZDLEBBK]]>
TwitterFacebookLinkedIn